MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jacasi.2026.06.017

Медицинская библиотека · JACC. Asia · 2026

Real-World Evaluation of a Nationally Mandated Risk Stratification Tool for Destination Therapy LVAD in Japan.

Imamura Teruhiko, Kinugawa Koichiro, Nishimura Takashi, Toda Koichi, Saiki Yoshikatsu, Niinami Hiroshi, Nunoda Shinichi, Matsumiya Goro, Arai Hirokuni, Yanase Masanobu, Fukushima Norihide, Nakatani Takeshi, Shiose Akira, Shibasaki Ikuko, Sakata Yasushi, Hatano Masaru, Ono Minoru, J-MACS Investigators

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Patient selection for destination therapy (DT) with durable left ventricular assist devices (LVADs) remains a major challenge in Asian advanced heart failure practice. In Japan, the J-MACS score is mandatorily calculated before DT implantation and directly influences eligibility decisions; however, its real-world prognostic performance in DT recipients remains unclear.

OBJECTIVES

The authors aimed to externally validate the predictability of the J-MACS score on mortality in a nationwide Japanese DT cohort.

METHODS

We conducted a nationwide registry-based analysis of patients undergoing HeartMate 3 implantation as DT between May 2021 and October 2025. The primary endpoint was 2-year all-cause mortality. Prognostic performance of the J-MACS score-based on age, prior cardiac surgery, serum creatinine, and central venous pressure-to-pulmonary artery wedge pressure ratio-was evaluated using multivariable Cox models and restricted mean survival time.

RESULTS

In total, 210 patients (median age, 60 years; 159 [76%] male) were followed for a median of 514 days (IQR: 257-730 days) after LVAD implantation. The J-MACS score independently predicted mortality (adjusted hazard ratio: 1.17, 95% CI: 1.02-1.36, P = 0.037). The 2-year cumulative mortality rates were 5.8% (95% CI: 2.0%-16.1%) in the low-risk group, 12.7% (95% CI 6.3%-24.6%) in the intermediate-risk group, and 28.6% (95% CI 14.6%-51.2%) in the high-risk group (P = 0.003 for comparison). The high-risk group had approximately 4 months shorter survival.

CONCLUSIONS

This nationwide real-world study provides the first validation of a nationally mandated DT eligibility algorithm. The J-MACS score may support risk-based clinical decision-making in Japanese DT practice.

Для цитирования: Imamura Teruhiko, Kinugawa Koichiro, Nishimura Takashi, Toda Koichi, Saiki Yoshikatsu, Niinami Hiroshi, Nunoda Shinichi, Matsumiya Goro, Arai Hirokuni, Yanase Masanobu, Fukushima Norihide, Nakatani Takeshi, Shiose Akira, Shibasaki Ikuko, Sakata Yasushi, Hatano Masaru, Ono Minoru, J-MACS Investigators. Real-World Evaluation of a Nationally Mandated Risk Stratification Tool for Destination Therapy LVAD in Japan.. JACC. Asia. 2026. DOI: 10.1016/j.jacasi.2026.06.017.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.